International Journal of Drug Delivery Technology
Volume 14, Issue 1

Investigation Few Biomarkers for Pantoea Infection with Systemic Lupus Erythematosus Patients

Burhan T Burhan1*, Layla S A Hassan2

1Department of Medical Laboratory Techniques, College of Health and Medical Techniques, Kufa, Al-Furat Al-Awsat Technical University, Al-Kufa, Iraq.

2Department of Community Health Techniques, College of Health and Medical Techniques, Kufa, Al-Furat Al-Awsat Technical University, Al-Kufa, Iraq. 

Received: 12th November, 2023; Revised: 12th December, 2023; Accepted: 19th December, 2023; Available Online: 25th March, 2024

ABSTRACT

Background: Systemic lupus erythematosus (SLE) is a disease known as systemic lupus erythematosus. SLE is an autoimmune condition in which the immune system attacks the body’s own tissues, leading to extensive tissue damage and inflammation in other organs. One of the most frequent causes of death and morbidity in SLE patients is infection. Patients with SLE may contract a genus of gram-negative bacteria called Pantoea. This study aims to find biomarkers for Pantoea infection in SLE patients in Iraq’s Najaf Governorate.

Methods: About 60 individuals with systemic lupus erythematosus from Al-Sader Medical City in Al-Najaf Province had blood samples taken at a specialized rheumatology and nephrology center between September 2022 and February 2023. Some bio-markers has been evaluated.

Results: The results of microbiological analyses indicate that 26/60 samples contain bacteria. Pantoea was discovered in 3 (11.6%) of the 26 specimens. Despite SLE, increased autoantibody levels in patients. The results of this analysis indicate a significant decrease in Hb, WBC, and platelet levels. In contrast to the control group, the serum levels of CD69, IL-21, and IL-35 increased significantly.

Conclusion: Pantoea produces elevated diagnostic and immunological parameters in SLE patients. Consequently, it is necessary to conduct assays to identify bacterial infections in patients, with a significant increase in CD69, IL-21, and IL-35 in the event that SLE patients are infected with bacteria.

Keywords: Systemic lupus erythematosus, Pantoea, Cluster of differentiation 69, Interleukin 21, Interleukin 35.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.08

How to cite this article: Burhan BT, Hassan LSA. Investigation Few Biomarkers for Pantoea Infection with Systemic Lupus Erythematosus Patients. International Journal of Drug Delivery Technology. 2024;14(1):45-49.

REFERENCES

  1. Cervera, R. (2008). Lessons from the “Euro-Phospholipid” project. Autoimmunity Reviews, 7(3), 174-178.f
  2. Mosca, , Tani, C., Aringer, M., Bombardieri, S., Boumpas, D., Cervera, R., ... & Carmona, L. (2011). Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmunity reviews, 10(7), 383-388.f
  3. Shoenfeld, Y., Gilburd, B., Abu-Shakra, M., Amital, H., Barzilai, , Berkun, Y., ... & Tomer, Y. (2008). The mosaic of autoimmunity: genetic factors involved in autoimmune diseases--2008. The Israel Medical Association journal: IMAJ, 10(1), 3-7.f
  4. Sherer, , Gorstein, A., Fritzler, M. J., & Shoenfeld, Y. (2004, October). Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. In Seminars in arthritis and rheumatism (Vol. 34, No. 2, pp. 501-537). WB Saunders.f
  5. Cuchacovich, R., & Gedalia, A. (2009). Pathophysiology and clinical spectrum of infections in systemic lupus Rheumatic Disease Clinics, 35(1), 75-93.f
  6. Al-Rayes, H., Al-Swailem, R., Arfin, M., Sobki, S., Rizvi, S., & Tariq, M. (2007). Lupus Around the World: Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus, 16(9), 755-763.f
  7. Cruz, A. T., Cazacu, A. C., & Allen, C. H. (2007). Pantoea agglomerans, a plant pathogen causing human disease. Journal of clinical microbiology, 45(6), 1989-1992.f
  8. AbdAlhussen, S., & Darweesh, M. F. (2016). Prevelance and antibiotic susceptibility patterns of Pantoea spp. isolated form clinical and environmental sources in Iraq. Int J ChemTech Res, 9(8), 430-437.f
  9. Walterson, M., & Stavrinides, J. (2015). Pantoea: insights into a highly versatile and diverse genus within the Enterobacteriaceae. FEMS microbiology reviews, 39(6), 968-984.f
  10. Liberto, C., Matera, G., Puccio, R., Lo Russo, T., Colosimo, E., & Focà, E. (2009). Six cases of sepsis caused by Pantoea agglomerans in a teaching hospital. The new microbiologica, 32(1), 119.f
  11. Gullo, A., Iscra, F., Di Capua, G., Berlot, G., Lucangelo, U., Chierego, M. L., ... & Tufano, R. (2005). Sepsis and organ dysfunction: an ongoing challenge. Minerva anestesiologica, 71(11), 671-699.f
  12. Mac Faddin, F. (1976). Biochemical tests for identification of medical bacteria. Williams & Wilkins Co.
  13. Xiang, , Qu, Y., Qian, S., Wang, R., Wang, Y., Jin, Y., ... & Ding,(2022). Association between systemic lupus erythematosus and disruption of gut microbiota: A meta-analysis. Lupus Science & Medicine, 9(1), e000599.f
  14. Durcan, L., O’Dwyer, T., & Petri, M. (2019). Management strategies and future directions for systemic lupus erythematosus in adults. The Lancet, 393(10188), 2332-2343.f
  15. Fava, A., & Petri, M. (2019). Systemic lupus erythematosus: diagnosis and clinical management. Journal of autoimmunity, 96, 1-13.f
  16. Cuchacovich, R., & Gedalia, A. (2009). Pathophysiology and clinical spectrum of infections in systemic lupus Rheumatic Disease Clinics, 35(1), 75-93.f
  17. de Maio Carrillho, C. M., Gaudereto, J. J., Martins, R. C. R., de Castro Lima, A. C., de Oliveira, L. M., Urbano, M. R.,... & Costa, S. F. (2017). Colistin-resistant Enterobacteriaceae infections: clinical and molecular characterization and analysis of in vitro synergy. Diagnostic Microbiology and Infectious Disease, 87(3), 253-257.f
  18. Cheng, , Liu, C. Y., Tsai, H. Y., Hsu, M. S., Yang, C. J., Huang,T., ... & Hsueh, P. R. (2013). Bacteremia caused by Pantoea agglomerans at a medical center in Taiwan, 2000–2010. Journal of Microbiology, Immunology and Infection, 46(3), 187-194.f
  19. Flores Popoca, O., Miranda García, M., Romero Figueroa,S., Mendoza Medellín, A., Sandoval Trujillo, H., Silva Rojas,
  20. V., & Ramírez Durán, N. (2012). Pantoea agglomerans in immunodeficient patients with different respiratory symptoms. The Scientific World Journal, 2012.
  21. Dutkiewicz, J., Maćkiewicz, B., & Lemieszek, M. (2017). Pantoea agglomerans: a mysterious bacterium of evil and good. LAP LAMBERT Academic Publishing.f Dutkiewicz, J., Mackiewicz, B., Lemieszek, M. K., Golec, M., Skórska, , Góra-Florek, A., & Milanowski, J. (2016). Pantoea agglomerans: a mysterious bacterium of evil and good. P. 2. Deleterious effects: Dust-borne endotoxins and allergens-focus on grain dust, other agricultural dusts and wood dust. Annals of Agricultural and Environmental Medicine, 23(1).f
  22. Qiu, C. C., Caricchio, R., & Gallucci, S. (2019). Triggers of autoimmunity: the role of bacterial infections in the extracellular exposure of lupus nuclear Frontiers in immunology, 10, 2608.f
  23. Gieseck, L., Wilson, M. S., & Wynn, T. A. (2018). Type 2 immunity in tissue repair and fibrosis. Nature Reviews Immunology, 18(1), 62-76.f
  24. Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019). Immunoneuropsychiatry—novel perspectives on brain disorders. Nature Reviews Neurology, 15(6), 317-328.f
  25. Hervier, B., Beziat, V., Haroche, J., Mathian, A., Lebon, P., Ghillani‐Dalbin, P., ... & Vieillard, V. (2011). Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon‐γ production in patients with active disease. Arthritis & Rheumatism, 63(6), 1698-1706.f
  26. Rus, V., Zernetkina, V., Puliaev, R., Cudrici, C., Mathai, S., & Via, S. (2005). Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clinical Immunology, 117(1), 48-56.f
  27. Ettinger, R., Kuchen, S., & Lipsky, P. E. (2008). Interleukin 21 as a target of intervention in autoimmune disease. Annals of the rheumatic diseases, 67(Suppl 3), iii83-iii86.f
  28. Guan, Y., Leng, R. X., Khan, M. I., Qureshi, H., Li, X. P., Ye,D. Q., & Pan, H. F. (2017). Interleukin-35: a potential therapeutic agent for autoimmune diseases. Inflammation, 40, 303-310.f